Clinical Trials Logo
  1. Home
  2. Body Dysmorphic Disorder
  3. NCT00842309

D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder — BDD/DCS  

Body Dysmorphic Disorder Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder

Clinical Trial Summary

The purpose of the study is to conduct a double-blind, placebo-controlled study of D-cycloserine (DCS) augmentation of behavior therapy in individuals with Body Dysmorphic Disorder (BDD). Specifically, we intend to randomize 50 individuals with BDD to receive either DCS (n = 25) or placebo (n = 25) one hour prior to 8 of 10 behavior therapy sessions.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00842309
Study type Interventional
Source Massachusetts General Hospital
Contact
Status Completed
Phase Early Phase 1
Start date November 2008
Completion date August 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT02635152 - Interpretation Bias Modification for Body Dysmorphic Disorder N/A
Completed NCT03673046 - Waitlist-Control Trial of Smartphone Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder (BDD) N/A
Recruiting NCT05402475 - Online Cognitive Behavioural Therapy Intervention for Body Dysmorphic Disorder N/A
Withdrawn NCT02843451 - Milk Thistle in Body Dysmorphic Disorder Phase 2
Completed NCT02010619 - Internet Delivered CBT for Body Dysmorphic Disorder N/A
Completed NCT00245635 - Fluoxetine in Pediatric Body Dysmorphic Disorder Phase 4
Completed NCT02808702 - Brain Correlates of Self-Focused Processing N/A
Completed NCT01002326 - Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder N/A
Active, not recruiting NCT01075672 - Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals N/A
Completed NCT02671266 - Oxytocin Administration in BDD and OCD Phase 2
Completed NCT01038128 - An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder N/A
Completed NCT01398865 - Escitalopram Neuroimaging Supplement N/A
Completed NCT00265109 - Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Phase 4
Recruiting NCT04373629 - Perceptual Abnormalities and Their Malleability in BDD N/A
Completed NCT01453439 - Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder N/A
Completed NCT00871143 - Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD) N/A
Completed NCT00106223 - Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder N/A
Active, not recruiting NCT00211809 - CBT as an Adjunct to SRIs in the Treatment of BDD Phase 4